The report from the Association for Accessible Medicines highlights the impact that accessible generic and biosimilar medicines have had on patients nationwide.
If passed, the legislation would require pharmacy-negotiated price concessions, payment and fees to be included in negotiated prices at the point-of-sale under Part D of the Medicare program.
Erik Komendant will assume the role of the Association for Accessible Medicines’ senior vice president of government affairs and Steven Selde will serve as director of the Biosimilars Council.
